Publications by authors named "Charles P B Vanderpool"
Article Synopsis
- Severe malaria (SM) leads to increased risk of invasive bacterial infections and demonstrates gastrointestinal permeability issues, particularly in children aged 6 months to 4 years.
- A study analyzed intestinal injury biomarkers, TFF3 and I-FABP, in 598 children with SM, revealing significant elevations in these markers compared to 120 healthy children, indicating intestinal injury is common among those with SM.
- Elevated TFF3 levels were linked to higher in-hospital mortality rates, as well as associations with acute kidney injury and acidosis, suggesting that potential interventions for intestinal repair could improve patient outcomes.
Background: Bronchopulmonary dysplasia (BPD) remains the most common late morbidity of preterm birth. Clinical care and research have largely focused on the pathogenesis and prevention of BPD. Preterm infants who develop BPD have significant medical needs that persist throughout their hospital course and continue after discharge, including those associated with growth and nutrition.
View Article and Find Full Text PDFNutrition and growth in infants with established bronchopulmonary dysplasia.
Pediatr Pulmonol
November 2021
Bronchopulmonary dysplasia (BPD) remains the most common late morbidity of preterm birth. Ongoing clinical care and research have largely focused on the pathogenesis and prevention of BPD in preterm infants. However, preterm infants who develop BPD have significant medical needs that persist throughout their neonatal intensive care unit course and continue post-discharge, including those associated with growth and nutrition.
View Article and Find Full Text PDFSafety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
JPEN J Parenter Enteral Nutr
September 2021
Background: This analysis assessed combined safety data from 4 clinical studies of teduglutide in pediatric patients with short-bowel syndrome-associated intestinal failure (SBS-IF).
Methods: Safety data from teduglutide-treated patients in 4 clinical trials were pooled. The completed 12-week and 24-week phase 3 core studies (NCT01952080/EudraCT 2013-004588-30 and NCT02682381/EudraCT 2015-002252-27) enrolled children aged 1-17 years with SBS-IF.
Artificial Intelligence and Gastroenterology: Expanding Technology.
J Pediatr Gastroenterol Nutr
February 2021